Independent analysis for European life sciences leaders
Life Sciences Commercial Transformation in Europe
disrupting.healthcare examines the commercial shifts reshaping pharma, MedTech and digital health in Europe: operating models, AI, regulation, market access, evidence and execution.
The Moat Is Moving Beyond the Molecule
Europe discovers well. The strategic question is who industrialises the science—and who captures the value.
Written by Piotr Wrzosinski, a life sciences commercial transformation leader with 20+ years across BD, Roche, Janssen/J&J, Pfizer, Accenture and IQVIA. At BD, he is building EMEA commercial transformation infrastructure across 30+ markets.
Start here
Three analyses that define the publication
Commercial transformation, digital health scale and European market intelligence—viewed through the decisions operators actually have to make.
01 · Commercial operating models
AI-Powered Commercial Operating Models in Life Sciences
AI adoption is not operating-model redesign. Decision rights, data, governance and roles must change before commercial AI can scale beyond disconnected pilots.
02 · Commercialisation
Digital Health Commercialisation in Europe
Regulatory access is only permission to compete. Integration, evidence, adoption and reimbursement determine who scales.
03 · Market intelligence
European HealthTech Market Map 2026
A sourced view of the companies, funding signals and business models shaping European digital health and life-sciences infrastructure.
The Weekly Signal
What matters in European life sciences
A weekly editorial briefing on the regulatory, commercial, scientific and capital-market moves reshaping pharma, MedTech and digital health in Europe.
Primary sources wherever available. Analysis separated from reported fact. Written for operators, not spectators.
The Moat Is Moving Beyond the Molecule
Europe’s industrialisation gap is becoming the strategic issue behind the science.
The Label Is the Strategy
Where evidence, regulatory definition and commercial value quietly become the same decision.
The System Is Becoming the Product
Advantage is moving from the asset alone to the system that makes adoption possible.
Explore the publication
Three lenses on how innovation works in Europe
01
Commercialization
Operating models, go-to-market choices and the realities of cross-market execution.
03
Regulation & Market Access
Evidence, reimbursement and the rules determining whether innovation reaches patients.
Independent analysis. No sponsored placements. Sources linked.